300194 福安药业
已收盘 07-26 15:00:00
资讯
新帖
简况
福安药业(300194.SZ)：注射用伏立康唑收到药品注册证书
智通财经 · 07-24
福安药业(300194.SZ)：注射用伏立康唑收到药品注册证书
福安药业：截止7月20日，公司股东户数为40466户
证券之星 · 07-23
福安药业：截止7月20日，公司股东户数为40466户
福安药业(300194.SZ)发预增，预计半年度净利润2.05亿元至2.25亿元，同比增长27.42%至39.85%
智通财经 · 07-21
福安药业(300194.SZ)发预增，预计半年度净利润2.05亿元至2.25亿元，同比增长27.42%至39.85%
福安药业最新公告：上半年净利同比预增27.42%-39.85%
证券之星 · 07-21
福安药业最新公告：上半年净利同比预增27.42%-39.85%
福安药业(300194)7月10日股东户数4.1万户，较上期减少0.46%
证券之星 · 07-16
福安药业(300194)7月10日股东户数4.1万户，较上期减少0.46%
福安药业：公司子公司的建设项目将在前期工作完成后开展
证券之星 · 07-02
福安药业：公司子公司的建设项目将在前期工作完成后开展
福安药业：子公司己酮可可碱注射液获药品注册证书 将进一步丰富其产品线
中国财富通 · 06-25
福安药业：子公司己酮可可碱注射液获药品注册证书 将进一步丰富其产品线
福安药业最新公告：子公司药品己酮可可碱注射液获注册证书
证券之星 · 06-25
福安药业最新公告：子公司药品己酮可可碱注射液获注册证书
福安药业(300194.SZ)：己酮可可碱注射液获药品注册证书
智通财经 · 06-25
福安药业(300194.SZ)：己酮可可碱注射液获药品注册证书
福安药业：子公司收到化学原料药上市申请批准通知书 将进一步丰富其产品线
中国财富通 · 06-24
福安药业：子公司收到化学原料药上市申请批准通知书 将进一步丰富其产品线
福安药业：截止2024年6月20日，公司股东户数为41194户
证券之星 · 06-24
福安药业：截止2024年6月20日，公司股东户数为41194户
福安药业最新公告：子公司获吲哚布芬化学原料药上市批准
证券之星 · 06-24
福安药业最新公告：子公司获吲哚布芬化学原料药上市批准
福安药业(300194.SZ)：吲哚布芬原料药上市申请获批
智通财经 · 06-24
福安药业(300194.SZ)：吲哚布芬原料药上市申请获批
福安药业最新公告：子公司收到药品补充申请批准通知书
证券之星 · 06-14
福安药业最新公告：子公司收到药品补充申请批准通知书
福安药业最新公告：子公司帕拉米韦注射液获得药品注册证书
证券之星 · 06-13
福安药业最新公告：子公司帕拉米韦注射液获得药品注册证书
福安药业(300194.SZ)获“帕拉米韦注射液”药品注册证书
智通财经 · 06-13
福安药业(300194.SZ)获“帕拉米韦注射液”药品注册证书
福安药业最新公告：子公司收到化学原料药上市申请批准通知书
证券之星 · 06-12
福安药业最新公告：子公司收到化学原料药上市申请批准通知书
福安药业(300194.SZ)：化学原料药“恩格列净”上市申请获批
智通财经 · 06-12
福安药业(300194.SZ)：化学原料药“恩格列净”上市申请获批
福安药业最新公告：子公司收到药品注册证书
证券之星 · 05-28
福安药业最新公告：子公司收到药品注册证书
福安药业(300194.SZ)：获得两项药品注册证书
智通财经 · 05-28
福安药业(300194.SZ)：获得两项药品注册证书
加载更多
公司概况
公司名称：
福安药业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
2011-03-22
主营业务：
福安药业(集团)股份有限公司主要从事化学药品的研发、生产、销售。主要产品有抗生素类（包括原料药、制剂不同规格）、抗肿瘤类、特色专科药类等药物。
发行价格：
41.88
{"stockData":{"symbol":"300194","market":"SZ","secType":"STK","nameCN":"福安药业","latestPrice":3.95,"timestamp":1721977380000,"preClose":3.93,"halted":0,"volume":14099300,"delay":0,"floatShares":968000000,"shares":1190000000,"eps":0.2256,"marketStatus":"已收盘","marketStatusCode":5,"change":0.02,"latestTime":"07-26 15:00:00","open":3.92,"high":3.98,"low":3.91,"amount":55688800,"amplitude":0.0178,"askPrice":3.95,"askSize":746,"bidPrice":3.94,"bidSize":2364,"shortable":0,"etf":0,"ttmEps":0.2256,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"adr":0,"adjPreClose":3.93,"symbolType":"stock","openAndCloseTimeList":[[1721957400000,1721964600000],[1721970000000,1721977200000]],"highLimit":4.32,"lowLimit":3.54,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1189712382,"pbRate":1.09,"roa":"--","roe":"2.91%","epsLYR":0.19,"committee":-0.253625,"marketValue":4699000000,"floatMarketCap":3823000000,"peRate":17.508865,"changeRate":0.0051,"turnoverRate":0.0146,"status":0},"requestUrl":"/m/hq/s/300194","defaultTab":"news","newsList":[{"id":"2453736850","title":"福安药业(300194.SZ)：注射用伏立康唑收到药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2453736850","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453736850?lang=zh_cn&edition=full","pubTime":"2024-07-24 16:55","pubTimestamp":1721811301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)公告，公司全资子公司福安药业集团烟台只楚药业有限公司(简称“只楚药业”)于近日收到国家药品监督管理局签发的药品注册证书，药品名称为注射用伏立康唑。注射用伏立康唑是一种广谱的三唑类抗真菌药，主要适用于治疗成人和2岁及2岁以上儿童患者的真菌感染。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0132","300194","BK0028","BK0239"],"gpt_icon":0},{"id":"2453302081","title":"福安药业：截止7月20日，公司股东户数为40466户","url":"https://stock-news.laohu8.com/highlight/detail?id=2453302081","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453302081?lang=zh_cn&edition=full","pubTime":"2024-07-23 18:04","pubTimestamp":1721729051,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业07月23日在投资者关系平台上答复投资者关心的问题。投资者：你好，请问截止7月20日最新股东人数是多少，谢谢您福安药业董秘：截止7月20日，公司股东户数为40466户，谢谢！本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300034755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0028","BK0060","300194","BK0239"],"gpt_icon":0},{"id":"2453929225","title":"福安药业(300194.SZ)发预增，预计半年度净利润2.05亿元至2.25亿元，同比增长27.42%至39.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453929225","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453929225?lang=zh_cn&edition=full","pubTime":"2024-07-21 16:41","pubTimestamp":1721551274,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)披露2024年半年度业绩预告，公司预计归属于上市公司股东的净利润2.05亿元至2.25亿元，同比增长27.42%至39.85%;扣除非经常性损益后的净利润1.9亿元至2.1亿元，同比增长32.90%至46.89%。报告期，部分产品销量的增长带动营业收入增长;国家集采中标产品占比提高，销售费用占营业收入的比率下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300194"],"gpt_icon":0},{"id":"2453222357","title":"福安药业最新公告：上半年净利同比预增27.42%-39.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453222357","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453222357?lang=zh_cn&edition=full","pubTime":"2024-07-21 16:01","pubTimestamp":1721548901,"startTime":"0","endTime":"0","summary":"福安药业公告，预计上半年净利2.05亿元–2.25亿元，同比增长27.42%-39.85%。部分产品销量的增长带动营业收入增长；国家集采中标产品占比提高，销售费用占营业收入的比率下降。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072100006270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0060","300194","BK0132"],"gpt_icon":0},{"id":"2451963541","title":"福安药业(300194)7月10日股东户数4.1万户，较上期减少0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451963541","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451963541?lang=zh_cn&edition=full","pubTime":"2024-07-16 16:58","pubTimestamp":1721120312,"startTime":"0","endTime":"0","summary":"证券之星消息，近日福安药业披露，截至2024年7月10日公司股东户数为4.1万户，较6月20日减少191.0户，减幅为0.46%。在化学制药行业个股中，福安药业股东户数高于行业平均水平，截至7月10日，化学制药行业平均股东户数为3.29万户。从股价来看，2024年6月20日至2024年7月10日，福安药业区间跌幅为0.8%，在此期间股东户数减少191.0户，减幅为0.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071600034080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300194","BK0028","BK0060"],"gpt_icon":0},{"id":"2448136496","title":"福安药业：公司子公司的建设项目将在前期工作完成后开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2448136496","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448136496?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:04","pubTimestamp":1719914681,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)07月02日在投资者关系平台上答复投资者关心的问题。投资者：请问董秘:烟台的生物制药园区现在建设的怎样了?三通一平做好了吗?施工队进场了吗?福安药业董秘：您好，公司子公司的建设项目将在前期工作完成后开展，谢谢！投资者：你好董秘，公司中报业绩预报整理好了吗福安药业董秘：公司中报预约于2024年8月底披露，请您关注有关公告信息，谢谢！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200028169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0028","BK0060","300194","BK0239"],"gpt_icon":0},{"id":"2446818112","title":"福安药业：子公司己酮可可碱注射液获药品注册证书 将进一步丰富其产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2446818112","media":"中国财富通","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446818112?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:58","pubTimestamp":1719309538,"startTime":"0","endTime":"0","summary":"中国财富通6月25日 - 福安药业（300194）公告称，公司全资子公司福安药业集团烟台只楚药业有限公司于近日收到国家药品监督管理局签发的药品注册证书，药品名称为己酮可可碱注射液。上述药品注册证书的获得将进一步丰富子公司产品线，提升其市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=xrnCkh%2Btdlc%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300194","BK0132","BK0239","BK0060","BK0028"],"gpt_icon":0},{"id":"2446899390","title":"福安药业最新公告：子公司药品己酮可可碱注射液获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446899390","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446899390?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:26","pubTimestamp":1719303993,"startTime":"0","endTime":"0","summary":"福安药业公告，子公司只楚药业于近日收到国家药品监督管理局签发的药品注册证书，药品名称为己酮可可碱注射液。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500030510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0028","BK0060","300194","BK0239"],"gpt_icon":0},{"id":"2446589588","title":"福安药业(300194.SZ)：己酮可可碱注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446589588","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446589588?lang=zh_cn&edition=full","pubTime":"2024-06-25 15:52","pubTimestamp":1719301928,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)公告，公司全资子公司福安药业集团烟台只楚药业有限公司(简称“只楚药业”)于近日收到国家药品监督管理局签发的药品注册证书，药品名称为己酮可可碱注射液，主要用于治疗外周动脉疾病(间歇性跛行或静息痛);内耳循环障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK0239","300194","BK0028","BK0060"],"gpt_icon":0},{"id":"2445253360","title":"福安药业：子公司收到化学原料药上市申请批准通知书 将进一步丰富其产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2445253360","media":"中国财富通","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445253360?lang=zh_cn&edition=full","pubTime":"2024-06-24 17:24","pubTimestamp":1719221041,"startTime":"0","endTime":"0","summary":"中国财富通6月24日 - 福安药业（300194）公告称，全资子公司福安药业集团重庆博圣制药有限公司于近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书，原料药名称为吲哚布芬。吲哚布芬片为抗血栓形成药，适应症为动脉硬化引起的缺血性心血管病变、缺血性脑血管病变、静脉血栓形成。也可用于血液透析时预防血栓形成。上述原料药产品获得上市批准将可以在国内上市制剂中使用，将进一步丰富子公司产品线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=JtqK3FAR7xw%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","300194","BK0060","BK0239","BK0028"],"gpt_icon":0},{"id":"2445028777","title":"福安药业：截止2024年6月20日，公司股东户数为41194户","url":"https://stock-news.laohu8.com/highlight/detail?id=2445028777","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445028777?lang=zh_cn&edition=full","pubTime":"2024-06-24 17:03","pubTimestamp":1719219800,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)06月24日在投资者关系平台上答复投资者关心的问题。投资者：请问截止到2024年6月20日股东户数是多少？谢谢福安药业董秘：截止2024年6月20日，公司股东户数为41194户，谢谢！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400023911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300194","BK0060","BK0239","BK0028"],"gpt_icon":0},{"id":"2445402836","title":"福安药业最新公告：子公司获吲哚布芬化学原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2445402836","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445402836?lang=zh_cn&edition=full","pubTime":"2024-06-24 16:52","pubTimestamp":1719219139,"startTime":"0","endTime":"0","summary":"福安药业公告，全资子公司博圣制药近日收到国家药监局签发的化学原料药吲哚布芬的上市申请批准通知书。吲哚布芬为抗血栓形成药，适应症包括动脉硬化引起的缺血性心血管病变、缺血性脑血管病变及静脉血栓形成。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400022211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0028","300194","BK0132"],"gpt_icon":0},{"id":"2445136042","title":"福安药业(300194.SZ)：吲哚布芬原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2445136042","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445136042?lang=zh_cn&edition=full","pubTime":"2024-06-24 16:20","pubTimestamp":1719217245,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)发布公告，公司全资子公司福安药业集团重庆博圣制药有限公司(简称“博圣制药”)于近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书。原料药名称为吲哚布芬，吲哚布芬片为抗血栓形成药，适应症为动脉硬化引起的缺血性心血管病变、缺血性脑血管病变、静脉血栓形成。也可用于血液透析时预防血栓形成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","300194","BK0132","BK0239","BK0060"],"gpt_icon":0},{"id":"2443149643","title":"福安药业最新公告：子公司收到药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2443149643","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443149643?lang=zh_cn&edition=full","pubTime":"2024-06-14 16:32","pubTimestamp":1718353942,"startTime":"0","endTime":"0","summary":"福安药业公告，全资子公司天衡制药近日收到国家药品监督管理局签发的药品补充申请批准通知书。枸橼酸托瑞米芬片通过仿制药质量和疗效一致性评价，主要用于治疗绝经后妇女雌激素受体阳性或不详的转移性乳腺癌。目前，该药品有3家企业通过一致性评价或视同通过一致性评价。此举将提升子公司产品的市场竞争力，但产品的生产、销售情况及对公司业绩的具体影响存在不确定性。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061400030093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0132","300194","BK0239","BK0060"],"gpt_icon":0},{"id":"2443571562","title":"福安药业最新公告：子公司帕拉米韦注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2443571562","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443571562?lang=zh_cn&edition=full","pubTime":"2024-06-13 16:35","pubTimestamp":1718267756,"startTime":"0","endTime":"0","summary":"福安药业公告，子公司只楚药业于近日收到国家药品监督管理局签发的帕拉米韦注射液药品注册证书。该药品主要用于治疗甲型或乙型流行性感冒。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300030370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0132","300194","BK0060"],"gpt_icon":0},{"id":"2443576416","title":"福安药业(300194.SZ)获“帕拉米韦注射液”药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2443576416","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443576416?lang=zh_cn&edition=full","pubTime":"2024-06-13 16:12","pubTimestamp":1718266320,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)公告，公司全资子公司福安药业集团烟台只楚药业有限公司(“只楚药业”)于近日收到国家药品监督管理局签发的“帕拉米韦注射液”药品注册证书。据悉，帕拉米韦主要用于治疗甲型或乙型流行性感冒。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","300194","BK0132","BK0239","BK0060"],"gpt_icon":0},{"id":"2442879275","title":"福安药业最新公告：子公司收到化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2442879275","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442879275?lang=zh_cn&edition=full","pubTime":"2024-06-12 16:50","pubTimestamp":1718182245,"startTime":"0","endTime":"0","summary":"福安药业公告，全资子公司博圣制药收到国家药品监督管理局签发的化学原料药上市申请批准通知书。恩格列净原料药主要用于治疗2型糖尿病，其上市批准将丰富子公司产品线。但产品生产销售时间和具体销售情况可能受GMP合规性检查进度、国家政策、市场环境变化等因素影响，存在不确定性。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061200031291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300194","BK0060","BK0028","BK0239","BK0132"],"gpt_icon":0},{"id":"2442558246","title":"福安药业(300194.SZ)：化学原料药“恩格列净”上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2442558246","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442558246?lang=zh_cn&edition=full","pubTime":"2024-06-12 16:43","pubTimestamp":1718181835,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)发布公告，公司全资子公司福安药业集团重庆博圣制药有限公司(“博圣制药”)于近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书。涉及药品：“恩格列净”，恩格列净主要用于治疗2型糖尿病。上述原料药产品获得上市批准将可以在国内上市制剂中使用，将进一步丰富子公司产品线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","300194","BK0060","BK0239","BK0028"],"gpt_icon":0},{"id":"2438344418","title":"福安药业最新公告：子公司收到药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2438344418","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438344418?lang=zh_cn&edition=full","pubTime":"2024-05-28 16:40","pubTimestamp":1716885613,"startTime":"0","endTime":"0","summary":"福安药业公告，全资子公司只楚药业、庆余堂分别于近日收到国家药品监督管理局签发的药品注册证书。奥硝唑片主要适用于治疗阿米巴虫病、泌尿生殖道毛滴虫病及兰氏贾第鞭毛虫病；治疗对本品敏感的厌氧菌引起的感染；预防外科手术可能引起的敏感厌氧菌感染；本品也可用于奥硝唑注射液治疗后的序贯治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052800029780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0132","300194","BK0060"],"gpt_icon":0},{"id":"2438734924","title":"福安药业(300194.SZ)：获得两项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2438734924","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438734924?lang=zh_cn&edition=full","pubTime":"2024-05-28 16:14","pubTimestamp":1716884057,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业 发布公告，公司全资子公司福安药业集团烟台只楚药业有限公司、福安药业集团庆余堂制药有限公司分别于近日收到国家药品监督管理局签发的药品注册证书，药品名称为奥硝唑片、注射用哌拉西林钠他唑巴坦钠。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK0028","BK0060","300194","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-03-22","address":"重庆市长寿区化南一路1号","stockEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":0.0367},{"period":"3month","weight":0.0204},{"period":"6month","weight":0.0204},{"period":"1year","weight":0.0152},{"period":"ytd","weight":-0.0867}],"companyName":"福安药业(集团)股份有限公司","boardCode":"AI0027","perCapita":"23918股","boardName":"医药制造业","registeredCapital":"118971万元","compareEarnings":[{"period":"1week","weight":-0.0307},{"period":"1month","weight":-0.0275},{"period":"3month","weight":-0.064},{"period":"6month","weight":-0.0066},{"period":"1year","weight":-0.1013},{"period":"ytd","weight":-0.0282}],"survey":" 福安药业(集团)股份有限公司主要从事化学药品的研发、生产、销售。主要产品有抗生素类（包括原料药、制剂不同规格）、抗肿瘤类、特色专科药类等药物。","serverTime":1722209149959,"listedPrice":41.88,"stockholders":"40466人(较上一季度减少1.31%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福安药业(300194)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福安药业(300194)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福安药业,300194,福安药业股票,福安药业股票老虎,福安药业股票老虎国际,福安药业行情,福安药业股票行情,福安药业股价,福安药业股市,福安药业股票价格,福安药业股票交易,福安药业股票购买,福安药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福安药业(300194)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福安药业(300194)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}